Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR NK Cells for Relapsed/Refractory B-cell Related Autoimmune Diseases
NCT06318533Phase 1Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in autoimmune disease. Primary endpoints: Incidence of Dose Limiting Toxicity at 52 weeks and Treatment Emergent Adverse Events at 52 weeks. Started Mar 2024; status: recruiting.
02
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT06318533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318533.